Compare Bristol-Myers Squibb Co (BMY) vs Modine Manufacturing Company (MOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Modine Manufacturing Company — how do they compare? Bristol-Myers Squibb Co trades at $63.95 (market cap $132.45B), while Modine Manufacturing Company trades at $198.81 (market cap $10.15B). The key difference: Bristol-Myers Squibb Co is far larger — about 13× Modine Manufacturing Company's market cap, and Bristol-Myers Squibb Co pays a 3.89% dividend while Modine Manufacturing Company pays none. Which is the better fit depends on your goals.
| BMY | MOD | |
|---|---|---|
Market Cap | $132.45B | $10.15B |
Sector | Health | Technology |
52-Week High | $65.89 | $306.89 |
52-Week Low | $42.60 | $119.68 |
Enterprise Value | $166.44B | $10.58B |
Dividend Yield | 3.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.72, up 0.89% today, with a bullish technical signal and strong earnings beats in recent quarters. The company shows robust profitability with a net income margin of 18.87% and ROE of 46.7%, though debt levels have risen. Recent news highlights a $2.3 billion manufacturing investment and merger speculation with AstraZeneca, driving investor interest.
BMY presents a mixed outlook: valuation metrics like P/E of 14.26 appear attractive, and analyst consensus targets $68.56. However, risks include patent expirations, high debt, and volatile cash flows. The stock's near-term performance hinges on merger developments and execution of growth initiatives amid competitive pressures.
Modine Manufacturing (MOD) trades at $195.60, up 1.6% on the day, with a bearish technical signal but strong fundamental growth driven by data center demand. The stock shows stretched valuation with a P/E of 71.27, yet has beaten earnings estimates for three consecutive quarters. Recent news highlights surging data center sales but also margin pressure and supply-chain constraints.
Outlook is mixed: robust revenue growth and a $319 consensus price target suggest upside, but high valuation, margin compression, and technical weakness pose risks. Investors should weigh strong analyst buy ratings against execution challenges in a competitive thermal management market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Modine Manufacturing Company
Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →
